Pathstone Family Office’s GSK GSK Stock Holding History

Pathstone Family Office’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$887K	Buy	24,394 +16,561	+211%	+$588K	0.01%	771
2023 Q2	$290K	Sell	7,833 -5,828	-43%	-$209K	﹤0.01%	973
2023 Q1	$488K	Sell	13,661 -30,317	-69%	-$1.06M	0.01%	706
2022 Q4	$2.79M	Sell	43,978 -7,473	-15%	-$249K	0.02%	410
2022 Q3	$1.52M	Buy	51,451 +31,161	+154%	+$1.18M	0.01%	541
2022 Q2	$1.11M	Buy	20,290 +14,329	+240%	+$791K	0.02%	318
2022 Q1	$327K	Sell	5,961 -113	-2%	-$6.14K	0.01%	716
2021 Q4	$337K	Buy	6,074 +540	+10%	+$28.1K	0.01%	672
2021 Q3	$265K	Sell	5,534 -1,546	-22%	-$77.7K	0.01%	715
2021 Q2	$354K	Buy	7,080 +2,039	+40%	+$98K	0.01%	585
2021 Q1	$225K	Buy	5,041 +562	+13%	+$25.5K	0.01%	574
2020 Q4	$247K	Buy	4,479 +2,724	+155%	+$125K	0.01%	234
2020 Q3	$82K	Buy	1,755 +571	+48%	+$28.6K	0.01%	302
2020 Q2	$61K	Sell	1,184 -150	-11%	-$7.7K	0.01%	289
2020 Q1	$64K	Buy	1,334 +378	+40%	+$20.2K	0.01%	265
2019 Q4	$561K	Sell	956 -190	-17%	-$10.6K	0.01%	276
2019 Q3	$61K	Buy	1,146 +202	+21%	+$10.4K	0.01%	247
2019 Q2	$48K	Sell	944 -142	-13%	-$7.13K	0.01%	331
2019 Q1	$56K	Buy	1,086 +156	+17%	+$7.79K	0.01%	288
2018 Q4	$45K	Buy	930 +538	+137%	+$26.5K	0.01%	194
2018 Q3	$20K	Hold	392	–	–	0.01%	144
2018 Q2	$20K	Sell	392 -195	-33%	-$9.82K	0.01%	104
2018 Q1	$29K	Buy	587 +195	+50%	+$9.08K	0.02%	135
2017 Q4	$17K	Hold	392	–	–	0.01%	96
2017 Q3	$20K	Sell	392 -80	-17%	-$4.06K	0.02%	102
2017 Q2	$25K	Hold	472	–	–	0.01%	261
2017 Q1	$25K	Buy	+472	New	+$23.9K	0.01%	224
2016 Q4	–	Sell	-392	Closed	-$21K	–	141
2016 Q3	$21K	Hold	392	–	–	0.02%	90
2016 Q2	$21K	Hold	392	–	–	0.02%	86
2016 Q1	$20K	Buy	+392	New	+$19.5K	0.04%	77
2015 Q4	–	Sell	-128	Closed	-$6K	–	124
2015 Q3	$6K	Hold	128	–	–	0.02%	114
2015 Q2	$7K	Hold	128	–	–	0.01%	101
2015 Q1	$7K	Hold	128	–	–	0.01%	99
2014 Q4	$7K	Hold	128	–	–	0.02%	85
2014 Q3	$7K	Hold	128	–	–	0.02%	247
2014 Q2	$9K	Hold	128	–	–	0.03%	97
2014 Q1	$9K	Hold	128	–	–	0.02%	98
2013 Q4	$9K	Buy	+128	New	+$8.3K	0.02%	136
2013 Q3	–	Sell	-18	Closed	-$1K	–	354
2013 Q2	$1K	Buy	+18	New	+$1.14K	﹤0.01%	354

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pathstone Family Office's GSK Position: Q3 2023 in Review

Pathstone Family Office increased its GSK (GSK) stake by 211% in Q3 2023, buying an estimated $588K and bringing the position to 24,394 shares worth $887K. The position accounts for 0.01% of the portfolio, ranked #771.

Pathstone Family Office first reported a position in GSK in Q2 2013 and has held it in 39 quarters since. The position peaked at $2.79M in Q4 2022. 846 funds tracked by Wall St. Rank hold GSK as of Q3 2023.

Pathstone Family Office held 24,394 shares of GSK worth $887K as of Q3 2023.
Pathstone Family Office bought 16,561 GSK shares in Q3 2023, an estimated $588K.
GSK made up 0.01% of Pathstone Family Office's portfolio in Q3 2023, its #771 holding.
Pathstone Family Office first reported a position in GSK in Q2 2013 and has held it in 39 quarters since.
Pathstone Family Office's GSK position peaked at $2.79M in Q4 2022.
846 funds tracked by Wall St. Rank held GSK as of Q3 2023.

Based on Pathstone Family Office's 13F filing for Q3 2023, filed 8 Nov 2023.